Significance of IL-34 and SDC-1 in the pathogenesis of RA cells and preclinical models
Clinical Immunology · 2023
DOI: 10.1016/j.clim.2023.109635 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Immunology, 2023. Verfasst von Osama Alzoubi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Rheumatology, the University of Illinois at Chicago, IL, USA. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, CSRD VA, BLRD VA.
Abstract (Originalsprache)
IL-34 shares a common receptor with M-CSF, while it can bind to other distinct receptors including protein-tyrosine phosphatase zeta (PTPζ), and syndecan1 (SDC-1). In physiological conditions, IL-34 has a critical role in the maintenance and development of Langerhans and microglial cells in part through PTPζ ligation. Conversely, in autoimmune diseases such as rheumatoid arthritis (RA), SDC-1-induced phosphorylation of M-CSFR was responsible for the pathological effect of IL-34 in patient cells and/or preclinical models. Intriguingly, enrichment of IL-34 is strongly linked to rheumatoid factor (RF), disease activity score (DAS)28, erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), and radiographic progression. In parallel, IL-34-induced naïve cell reprogramming into glycolytic RA CD14+CD86+GLUT1+ macrophage was dysregulated via M-CSFR or SDC-1 antibody therapy. Moreover, the inflammatory and erosive imprints of IL-34 arthritic mice were mitigated by glucose uptake inhibition and SDC-1, or RAG deficiency through nullifying macrophage metabolic rewiring and their ability to advance Th1/Th17 cell polarization. Consistently, IL-34-/- and SDC-1-/- mice could effectively impair CIA joint inflammation, osteoclast formation, and neovascularization by restraining monocyte infiltration as well as suppressing the inflammatory macrophage and T effector cell reconfiguration via metabolic deactivation. In conclusion, targeting IL-34/SDC-1 signaling, or its interconnected metabolites can uniquely intercept the crosstalk between glycolytic RA myeloid and lymphoid cells and their ability to trigger arthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Rheumatology, the University of Illinois at Chicago, IL, USA.
- Jesse Brown VA Medical Center, Chicago, IL, USA; Department of Medicine, Division of Rheumatology, the University of Illinois at Chicago, IL, USA.
- Jesse Brown VA Medical Center, Chicago, IL, USA; Department of Medicine, Division of Rheumatology, the University of Illinois at Chicago, IL, USA. Electronic address: shahrara@uic.edu.
Förderung
- NIAID NIH HHS
- CSRD VA
- BLRD VA
- U.S. Department of Veterans Affairs
- Rheumatology Research Foundation
- University of Illinois at Chicago
- RRF Foundation for Aging
- National Institutes of Health
Zitieren
APA
Alzoubi, O., Meyer, A., Gonzalez, T. P., Burgos, A. C., Sweiss, N., Zomorrodi, R. K., & Shahrara, S. (2023). Significance of IL-34 and SDC-1 in the pathogenesis of RA cells and preclinical models. Clinical Immunology. https://doi.org/10.1016/j.clim.2023.109635
Vancouver
Alzoubi O, Meyer A, Gonzalez TP, Burgos AC, Sweiss N, Zomorrodi RK, et al. Significance of IL-34 and SDC-1 in the pathogenesis of RA cells and preclinical models. Clinical Immunology. 2023. doi:10.1016/j.clim.2023.109635
BibTeX
@article{Alzoubi2023,
author = {Alzoubi, Osama and Meyer, Anja and Gonzalez, Tanya Pulido and Burgos, Adel C and Sweiss, Nadera and Zomorrodi, Ryan K and Shahrara, Shiva},
title = {Significance of IL-34 and SDC-1 in the pathogenesis of RA cells and preclinical models},
journal = {Clinical Immunology},
year = {2023},
doi = {10.1016/j.clim.2023.109635}
}
EUVIMED